IONS IONIS PHARMACEUTICALS INC

NEUTRAL Impact: 2/10 Insider Cluster (2 insiders)
Horizon days Filed Jun 16, 2026 Processed 4d 10h ago
Insider cluster: 2 insiders, $3.6M total
Latest settled — T+1d
IONS ▼ -0.26% at T+1d
NEUTRAL call ✗ call lost -0.26% · α vs SPY -1.04% · entry $74.31 → $74.12
Next anchor: T+5d in 3d
Last close $74.31 (close Jun 17) · -0.00% from $74.31 entry
Entry anchored
Jun 16, 03:59 PM ET
via Databento tick
T+1d
-0.26%
call -0.26% · α -1.04%
$74.12
settled 4d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 24d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Two IONIS insiders (a Director and the EVP/Chief Development Officer) sold a combined $3.59M in open-market shares after exercising stock options. The total sales represent only ~0.03% of the company's $12.2B market cap, making this a routine, liquidity-driven cluster with no material informational signal.

Key Financial Metrics

Direction
selling
Total Value
$3.6M
Insiders
2

Actionable Insight

No material signal from this cluster. Monitor for larger insider sales (>0.5% of market cap) or a cluster of open-market purchases by C-suite executives, which would carry stronger informational content.

Key Facts

  • Director Spencer R. Berthelsen sold 8,000 shares at $73.49 for $587,920 on June 15, 2026, following a derivative exercise.
  • EVP/Chief Development Officer Holly B. Kordasiewicz sold 41,004 shares at $73.09 for $3.00M on June 12, 2026, following derivative exercises.
  • Total insider sales of $3.59M represent ~0.03% of IONS' $12.2B market cap.
  • Both sales were preceded by option exercises, consistent with routine tax- or liquidity-driven transactions.

Financial Impact

Insider sales of $3.59M are trivial relative to $12.2B market cap (0.03%).

dilutioninsider ownership

Risk Factors

  • Insider sales could accelerate if the stock continues to appreciate, but current levels are routine.
  • Option exercises may increase share count modestly, but the impact is negligible.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (33 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IONS-1781645227794
8 reports for IONS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IONS — sortable, filterable
Type Now
Jun 16, 2026
4d ago
Insider Cluster
NEUTRAL ★ 2/10
$74.31 $74.12▼ −0.26%▼ −1.04%$74.31 (−0.00%)
Jun 12, 2026
8d ago
8-K
NEUTRAL ★ 3/10
$73.28 $73.96▲ +0.93%▼ −0.83%$74.31 (+1.41%)
Jun 8, 2026
12d ago
8-K
NEUTRAL ★ 3/10
$73.54 $74.58▲ +1.41%▲ +1.71%$74.31 (+1.05%)
May 28, 2026
23d ago
8-K
BULLISH ★ 7/10
$77.27 $76.29▼ −1.27%▼ −1.51%$74.31 (−3.83%)
Apr 28, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$71.50 $74.37▲ +4.01%▲ +4.02%$74.31 (+3.93%)
Apr 21, 2026
8w ago
8-K
BULLISH ★ 8/10
$74.71 $74.84▲ +0.17%▼ −0.84%$74.31 (−0.54%)
Apr 16, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$75.25 $75.71▲ +0.61%▼ −0.61%$74.31 (−1.25%)
Feb 25, 2026
16w ago
8-K
MIXED ★ 6/10
$80.87 $80.34▼ −0.66%▼ −0.11%$74.31 (−8.11%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (29h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access